Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Accuracy of Self-report for Cervical and Breast Cancer Screening

Accuracy of Self-report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening Health Services Research & Development Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating (...) Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Anderson J, Bourne D, Peterson, K, Mackey K. Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening. VA ESP Project #09-199; 2019. Download PDF: , Purpose The ESP Coordinating Center (ESP CC) is responding to a request from the VHA Performance Workgroup for an evidence brief on the accuracy of patient self-report for cervical and breast cancer screening. Findings from

2019 Veterans Affairs Evidence-based Synthesis Program Reports

2. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women?s Sexual Health

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women?s Sexual Health CONSENSUS RECOMMENDATIONS Managementofgenitourinarysyndromeofmenopauseinwomenwith orathighriskforbreastcancer:consensusrecommendationsfromThe North American Menopause Society and The International Society for the Study of Women’s Sexual Health Stephanie S (...) , CCD, NCMP, IF, FACOG, 14 Shari B. Goldfarb, MD, 15 and Sheryl A. Kingsberg, PhD 16 Abstract TheobjectiveofTheNorthAmericanMenopauseSociety(NAMS)andTheInternationalSocietyfortheStudyof Women’s Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendationswillassisthealthcareprovidersinmanagingGSMwithagoalofimprovingthecareandqualityof life

2019 The North American Menopause Society

3. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer Abemaciclib with an aromatase inhibitor Abemaciclib with an aromatase inhibitor for pre for previously untreated, hormone viously untreated, hormone receptor-positiv receptor-positive, HER2-negativ e, HER2-negative, locally e, locally advanced or metastatic breast cancer advanced or metastatic breast cancer T echnology appraisal guidance (...) . Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 15Contents Contents 1 Recommendations 4 2 Information about abemaciclib 5 3 Committee discussion 6 Current management 6 Clinical evidence 7 Indirect evidence: network meta-analyses 8 Abemaciclib and other CDK 4

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. (PubMed)

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable (...) anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded

2019 NEJM

5. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. (PubMed)

Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. BACKGROUND: Breast cancer is the most common type of cancer amongst women worldwide, and one distressing complication of breast cancer treatment is breast and upper-limb lymphoedema. There is uncertainty regarding the effectiveness of surgical interventions in both the prevention and management of lymphoedema affecting the arm after breast cancer treatment. OBJECTIVES: 1. To assess and compare (...) the efficacy of surgical interventions for the prevention of the development of lymphoedema (LE) in the arm after breast cancer treatment.2. To assess and compare the efficacy of surgical interventions for the treatment of established LE in the arm after breast cancer treatment. SEARCH METHODS: We searched the Cochrane Breast Cancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL

2019 Cochrane

6. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. (PubMed)

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. BACKGROUND: Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment (...) of early breast cancer. OBJECTIVES: To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. SEARCH METHODS: We searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 1 February 2018. SELECTION CRITERIA: Randomised controlled trials

2019 Cochrane

7. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. (PubMed)

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. METHODS: To clarify the relative benefits and risks (...) of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule

Full Text available with Trip Pro

2019 Lancet

8. Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Archives of Pathology & Laboratory Medicine Online - | | We have recently been experiencing high volumes of suspicious activity. Please answer the following CAPTCHA in order to continue on to the requested page. If you encounter diffculty, please contact us. Copyright © 2019 College of American Pathologists Published by the College of American Pathologists Allen Press, Inc. assists in the online publication

2019 College of American Pathologists

9. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial 30509771 2019 01 09 1474-5488 20 1 2019 Jan The Lancet. Oncology Lancet Oncol. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. 88-99 S1470-2045(18)30621-1 10.1016/S1470-2045(18)30621-1 (...) The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer. This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone

2019 EvidenceUpdates

10. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Signal - Common osteoporosis drugs may prevent breast cancer spreading to bone Dissemination Centre Discover Portal NIHR DC Discover Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However (...) , the overall benefits may be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breast cancer or advanced breast cancer with or without bone involvement. The reviewers

2019 NIHR Dissemination Centre

11. Delaying chemotherapy after breast cancer surgery may reduce survival chances

Delaying chemotherapy after breast cancer surgery may reduce survival chances Signal - Delaying chemotherapy after breast cancer surgery may reduce survival chances Dissemination Centre Discover Portal NIHR DC Discover Delaying chemotherapy after breast cancer surgery may reduce survival chances Published on 31 January 2017 Delaying chemotherapy after breast cancer surgery may slightly decrease a woman’s chances of survival. A review found about a 5% increase in the relative risk of death. Many (...) women are offered chemotherapy soon after breast cancer surgery, called adjuvant chemotherapy. Chemotherapy is usually started after the surgical wounds have healed but the effect of any delay to this was unclear. These researchers calculated the risk from outcomes for almost 30,000 women treated with adjuvant chemotherapy, from studies in Europe and North America. The absolute risk of death for any woman will depend on her individual cancer stage and characteristics. A four week delay could add

2019 NIHR Dissemination Centre

12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer T T umour profiling tests to guide adjuvant umour profiling tests to guide adjuvant chemother chemotherap apy decisions in early breast y decisions in early breast cancer cancer Diagnostics guidance Published: 19 December 2018 nice.org.uk/guidance/dg34 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 56Contents Contents 1 Recommendations 4 2 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostics and care pathways 7 3 The diagnostic tests 9 The interventions 9 The comparator 13 4 Evidence 14

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

13. Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer

Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer 1 Published 14 January 2019 1 a SMC2120 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE (...) : following a third resubmission assessed under the orphan equivalent process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: In combination with trastuzumab and docetaxel, in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly

2019 Scottish Medicines Consortium

14. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

2019 European Medicines Agency - EPARs

15. Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer

Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

2019 American Society of Clinical Oncology Guidelines

16. A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer

A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer 29730319 2018 11 24 1532-821X 99 12 2018 Dec Archives of physical medicine and rehabilitation Arch Phys Med Rehabil A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer. 2621-2636 S0003-9993(18)30280-6 10.1016/j.apmr.2018.03.026 To systematically evaluate the safety, feasibility, and effect (...) of exercise among women with stage II+ breast cancer. CINAHL, Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus were searched for articles published before March 1, 2017. Randomized, controlled, exercise trials involving at least 50% of women diagnosed with stage II+ breast cancer were included. Risk of bias was assessed and adverse event severity was classified using the Common Terminology Criteria

2019 EvidenceUpdates

17. Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. (PubMed)

Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. 30689703 2019 01 28 1569-8041 2019 Jan 23 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. 10.1093 (...) /annonc/mdz016 We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in HER2-positive early-stage breast cancer. Women (N=2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day

2019 Annals of oncology : official journal of the European Society for Medical Oncology

18. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. (PubMed)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. 30675515 2019 01 27 2374-4677 5 2019 NPJ breast cancer NPJ Breast Cancer MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. 5 10.1038/s41523-018-0097-z At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR (...) ) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). MONARCH 3 is a randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) plus nonsteroidal AI (1 mg anastrozole or 2.5 mg letrozole, daily). A total of 493 postmenopausal women with HR+, HER2- ABC with no prior systemic therapy in this setting were enrolled. The primary endpoint was investigator

Full Text available with Trip Pro

2019 NPJ breast cancer

19. Pertuzumab - HER2-positive breast cancer at high risk of recurrence

Pertuzumab - HER2-positive breast cancer at high risk of recurrence Cost effectiveness of Pertuzumab (Perjeta®) for use in combination with trastuzumab and chemotherapy, for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence The NCPE has issued a recommendation regarding the cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy). Following assessment of the applicant’s submission, the NCPE recommends (...) -positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease). The comparator is trastuzumab (in combination with chemotherapy). Final data, required by the NCPE, was received on 18th January 2019. 1. Comparative effectiveness of pertuzumab (in combination with trastuzumab and chemotherapy) Evidence was derived from the on-going phase III, randomised, double-blind, placebo- controlled APHINTY study. APHINITY evaluates pertuzumab

2019 National Centre for Pharmacoeconomics (Ireland)

20. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. (PubMed)

Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Background: Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or specific tumor subtype has rarely been evaluated. Objective: To characterize breast cancer risk in relation to recent childbirth. Design: Pooled analysis of individual-level data from 15 (...) prospective cohort studies. Setting: The international Premenopausal Breast Cancer Collaborative Group. Participants: Women younger than 55 years. Measurements: During 9.6 million person-years of follow-up, 18 826 incident cases of breast cancer were diagnosed. Hazard ratios (HRs) and 95% CIs for breast cancer were calculated using Cox proportional hazards regression. Results: Compared with nulliparous women, parous women had an HR for breast cancer that peaked about 5 years after birth (HR, 1.80 [95% CI

2018 Annals of Internal Medicine